Navigation Links
Signum Biosciences Names Braham Shroot as Chief Executive Officer
Date:8/5/2010

PRINCETON, N.J., Aug. 5 /PRNewswire/ -- Signum Biosciences, Inc. today announced the appointment of Dr. Braham Shroot, formerly CSO of Barrier Therapeutics, as Chief Executive Officer.  Dr. Shroot replaces Dr. Gregory Stock who will continue to remain active with the Company as a member of the board.

"Braham Shroot brings to Signum an outstanding track record of success in growing value at both start-up and major pharmaceutical companies including Barrier Therapeutics, DFB Bioscience, and Galderma," said Maxwell Stock, President of Signum Biosciences. "We welcome him to the Signum team and look forward to seeing the company progress under his leadership."  

"This is a very exciting time for Signum, with the commercialization of the company's first skin-care compound, Arazine™,  by its partner, Rohto Pharmaceutical in Japan," said Dr. Shroot. "I am equally enthusiastic about Signum's innovative pipeline which holds significant potential to help patients with difficult-to-treat chronic inflammatory and age related pathologies."

Braham Shroot Biography

Braham Shroot is the former CSO of Barrier Therapeutics, Inc., a public dermatology-focused pharmaceutical company, which was acquired by Stiefel Laboratories Inc., in August 2008.  Prior to Barrier, Dr. Shroot was CSO and Vice President of R&D for DFB Pharmaceuticals, Inc., a fully integrated private specialty pharmaceutical company with a focus on skin, wound care, and surgical markets. Before DFB, Dr. Shroot was at L'Oreal where he was Group Leader and eventually Vice General Manager of the newly created Galderma entity which he helped to establish.  Dr. Shroot earned his B.Sc. in Chemistry and Ph.D. in Organic Chemistry at Glasgow University, Scotland, UK.  He is also a board member of the Wound Healing Society, and associate Editor of the Journal of Investigative Dermatology.

About Signum Biosciences

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic candidates for inflammatory and neurodegenerative diseases. Signum's STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.

For more information please visit the Signum website: www.signumbiosciences.com


'/>"/>
SOURCE Signum Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... Stratevi, a boutique firm that partners ... Coast. It has opened an office in downtown Boston at 745 Atlantic Ave. ... more important to generate evidence on the value they provide, not just to patients, ...
(Date:5/21/2017)... ... 19, 2017 , ... Ovation Fertility scientists’ work is being ... Bioanalysts (AAB) and the College of Reproductive Biology (CRB) today and Saturday (May ... excellence in clinical laboratory services and regulations. , “We are pleased to ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science Center ... ripe for commercialization, and who are affiliated with the 21 partner academic and ... QED, now in its tenth round, is the first multi-institutional proof-of-concept program for ...
(Date:5/18/2017)... ... ... Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) portfolio company, today ... doubled in size over the past six months with the acquisition of businesses in ... CSM as Chief Financial Officer. Roger has over 25 years of experience in ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):